Trial Profile

A randomised, double-blind, placebo-controlled, phase III trial to study the effect of irbesartan on endothelial function of the retinal vasculature in patients with hypercholesterolemia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irbesartan (Primary)
Indications Cerebral ischaemia; Hypercholesterolaemia
Focus Pharmacodynamics

Most Recent Events

16 Dec 2024 Status changed from completed to withdrawn prior to enrolment.
01 Nov 2016 Results assessing effect of Valsartan on retinal capillary rarefaction in hypertensive patients (n=150) using patients data from this and other two trials (NCT01318395 and NCT01319344) published in the Journal of Clinical Hypertension (Greenwich)
03 Feb 2010 Actual initiation date (Nov 2009) added as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com